Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)
NCT00862745
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Ambulatory females ≥ 18 years old
- Urge Urinary Incontinence (subject-reported) for ≥ 3 months prior to Screening (Visit 1)
- On the 3IQ: Response b to Question 3: During the last 3 months, did you leak urine most often: b. When you had the urge or the feeling that you needed to empty your bladder, but could not get to the toilet fast enough?
- On a 3-day bladder diary, documentation of an average of 1 UUI episode per 24 hours (3 UUI episodes in 3 days)
- Capability of understanding and having signed the informed consent form after full discussion of the research nature of the treatment and its risk and benefits
- Ability to perform all procedures and tests required by the protocol
- Willingness to remain on stable medication regime for duration of the randomized controlled trial. Participants will be asked to not add new medications during the randomized controlled trial, such as diuretics and other medications which may affect their voiding pattern.
- Any condition that would contraindicate their usage of fesoterodine including:
hypersensitivity to the active drug (fesoterodine fumarate) and its ingredients or any
of the excipients, history of urinary retention, gastric retention, uncontrolled
narrow angle glaucoma, myasthenia gravis, severe hepatic impairment (Child Pugh C),
severe ulcerative colitis, toxic megacolon, fistula or a hole in your bladder or
rectum, birth defect leading to urine leakage, and urine leakage starting in
childhood.
- Clinically significant hepatic or renal disease.
- Neurologic conditions such as stroke, multiple sclerosis, spinal cord injury, or
Parkinson's disease.
- Symptomatic pelvic organ prolapse defined as participant report of feeling or seeing a
bulge outside the vagina within the past 3 months.
- History of lower urinary tract/pelvic surgery (e.g. surgery for incontinence in the
past 5 years, surgery in the past 6 months for prolapse or hysterectomy),
intra-vesical therapy (botox), and/or bulk injections within the past 6 months.
- A known history of interstitial cystitis or a significant pain component associated
with OAB symptoms, uninvestigated hematuria, urogenital cancer, interstitial or
external radiation to the pelvis or external genitalia.
- Urinary tract infection (UTI) as shown by the results of the urinalysis at screening
or recurrent urinary tract infection (RUTIs) defined as treatment for UTI >3 times in
the last year.
- Use of any electrostimulation, bladder training, or pelvic floor exercises (with
certified incontinence practitioners) within 4 weeks of Screening.
- Received study medication in any previous fesoterodine clinical trial.
- Prior failure for either efficacy or tolerability of ≥ 2 OAB medications in the last
year. (failure: inadequate symptom control after two medications for a minimum of one
month each)
- Has been treated within 2 weeks prior to Screening and/or is currently being treated
with: - Any drug treatment for overactive bladder, including antimuscarinic OAB
medications.
- Any drugs with significant anticholinergic and antispasmodic effects (see exception
for tricyclic antidepressants below)
- Has started treatment with tricyclic antidepressants or estrogens within 4 weeks prior
to Screening and/or is not on a stable dose.
- Intermittent or unstable use of diuretics. Treatment with diuretics initiated within 2
weeks prior to baseline is not permitted.
- Treatment with potent CYP3A4 inhibitors, such as clarithromycin, ketoconazole, and
itraconazole within 2 weeks prior to Screening.
- Administration of medications capable of inducing hepatic enzyme metabolism or
transport (e.g., barbiturates, rifampicin, carbamazepine, phenytoin, primidone, or St.
John's Wort) in the past 30 days.
- Previously received any investigational drug within 30 days prior to trial entry.
- Alcohol and/or any other drug abuse in the opinion of the investigator.
- Participants who are pregnant, nursing, or with a positive urine pregnancy test or who
are intending to become pregnant within 3 months after the completion of the trial.
- Participants that have been pregnant (> 20 weeks gestation) in the previous 6 months.
- Participants of childbearing potential who are heterosexually active but unwilling or
unable to use an adequate form of contraception to prevent pregnancy during the study.
Reliable contraceptive methods may include intrauterine devices (IUD), contraceptive
pills of combination type, hormonal implants, injectable contraceptives or latex
condoms with a spermicide.
- Participants who have any medical (including known history of major hematological,
renal, cardiovascular, or hepatic abnormalities) or psychological condition or social
circumstances that would impair their ability to participate reliably in the trial, or
those who may increase the risk to themselves or others by participating.
- Participants who, in the opinion of the investigator, are not likely to complete the
trial for whatever reason.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Birmingham, Alabama
- San Diego, California
- San Francisco, California
- Iowa City, Iowa
- Ann Arbor, Michigan
- Albuquerque, New Mexico
- Portland, Oregon
- Philadelphia, Pennsylvania
- Pittsburgh, Pennsylvania
- Providence, Rhode Island
- Memphis, Tennessee
- San Antonio, Texas
- Charlottesville, Virginia
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES) | |||
Official Title ICMJE | A Multi-center, Randomized, Placebo-controlled Clinical Trial Comparing Fesoterodine to Placebo in Women Diagnosed With Urge Urinary Incontinence by the 3 Incontinence Questions (3IQ). Followed by a Multi-center Open Label Clinical Cohort Study of Long-term Effects of Treatment With Fesoterodine. | |||
Brief Summary | Six hundred and thirty-six women diagnosed with urge urinary incontinence (UUI) by a three-item self-administered questionnaire (3IQ) will be randomized to 12 weeks of fesoterodine or matching placebo. The study will take place at up to 14 clinical sites in the US. All participants who complete the 12-week randomized trial will be offered open-label fesoterodine for an additional 9 months. The hypothesis of the randomized controlled trial is that among women diagnosed with urge incontinence using the 3IQ, fesoterodine is more effective than placebo in reducing the mean number of urge incontinence episodes per day. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 4 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment | |||
Condition ICMJE |
| |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Warsi QA, Huang AJ, Hess R, Arya LA, Richter HE, Bradley CS, Rogers RG, Myers DL, Johnson KC, Winkelman WD, Gregory WT, Kraus SR, Schembri M, Brown JS, Stone KL, Subak LL. Association of Pharmacologic Treatment of Urgency Urinary Incontinence With Sleep Quality and Daytime Sleepiness. Obstet Gynecol. 2018 Feb;131(2):204-211. doi: 10.1097/AOG.0000000000002443. | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 645 | |||
Original Estimated Enrollment ICMJE | 636 | |||
Actual Study Completion Date ICMJE | May 2011 | |||
Actual Primary Completion Date | May 2010 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | Yes | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00862745 | |||
Other Study ID Numbers ICMJE | GA0221IX | |||
Has Data Monitoring Committee | Yes | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Jeanette Brown, University of California, San Francisco | |||
Study Sponsor ICMJE | University of California, San Francisco | |||
Collaborators ICMJE | Pfizer | |||
Investigators ICMJE |
| |||
PRS Account | University of California, San Francisco | |||
Verification Date | October 2011 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |